Top stories in endocrinology: FDA issues complete response letter for sotaglifozin, new test reliably diagnoses diabetes
Among the most-read stories in endocrinology last week were the FDA’s explanation for not approving sotaglifozin’s application as it currently stands and data showing the results of a new point-of-care HbA1c test for diabetes “highly correlated” with industry standards.
Other popular stories include benefits for adults receiving metformin and reports from Healio’s live coverage of the Androgen Society 2nd Annual Meeting regarding how testosterone helps women with low sexual desire and men with hypogonadism. – by Janel Miller
FDA issues complete response letter for sotagliflozin
The FDA has issued a complete response letter regarding a new drug application for oral sotagliflozin, a first-in-class dual SGLT1 and SGLT2 inhibitor for adult with type 1 diabetes, according to a press release from Sanofi and Lexicon. Read more.
HbA1c point-of-care test reliably diagnoses diabetes
A point-of-care HbA1c test using either finger stick or venous blood sampling can be used to accurately diagnose diabetes in adults, according to findings published in the Journal of Diabetes Science and Technology. Read more.
Metformin lowers long-term diabetes risk
Metformin was shown to have long-term protective effects against diabetes development in adults at greatest risk, especially those with higher HbA1c levels and women who have had gestational diabetes, according to findings published in Diabetes Care. Read more.
Testosterone improves libido, quality of life in women with low sexual desire
NEW ORLEANS — Premenopausal and postmenopausal women reporting a persistent, low libido that profoundly impairs quality of life can experience an improvement in symptoms with transdermal testosterone, but clinicians must consider several important points before prescribing the therapy, a speaker said. Read more.
Testosterone therapy reduces CV events, death in men with hypogonadism
NEW ORLEANS — A speaker here said low testosterone is associated with increased all-cause and cardiovascular mortality, and testosterone replacement therapy in men with a confirmed diagnosis of hypogonadism is associated with reduced CV events and CV death. Read more.